Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Oct 11, 2023 • 2:00 pm EST

Annual Meeting of Shareholders

Oct 10, 2023 • 1:00 pm EST